229 results match your criteria: "a Center of Molecular Immunology (CIM); Immunobiology Division; Atabey; Havana Cuba.[Affiliation]"
PLoS One
January 2025
Immunology and Immunotherapy Division, Center of Molecular Immunology (CIM), Havana, Cuba.
SARS-CoV-2 has continued spreading around the world in recent years since the initial outbreak in 2019, frequently developing into new variants with greater human infectious capacity. SARS-CoV-2 and its mutants use the angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor, which has triggered several therapeutic strategies against COVID-19 relying on the use of ACE2 recombinant proteins as decoy receptors. In this work, we propose an ACE2 silent Fc fusion protein (ACE2-hFcLALA) as a candidate therapy against COVID-19.
View Article and Find Full Text PDFSci Rep
November 2024
Center for Infectious Medicine (CIM), Department of Medicine Huddinge, Karolinska Institutet, ANA Futura, Huddinge, 141 52, Sweden.
Host-directed therapies aiming to strengthen the body's immune system, represent an underexplored opportunity to improve treatment of tuberculosis (TB). We have previously shown in Mycobacterium tuberculosis (Mtb)-infection models and clinical trials that treatment with the histone deacetylase (HDAC) inhibitor, phenylbutyrate (PBA), can restore Mtb-induced impairment of antimicrobial responses and improve clinical outcomes in pulmonary TB. In this study, we evaluated the efficacy of different groups of HDAC inhibitors to reduce Mtb growth in human immune cells.
View Article and Find Full Text PDFFront Oncol
October 2024
Immunology and Immunotherapy Division, Center of Molecular Immunology (CIM), Havana, Cuba.
Despite the cumulative evidence supporting HER3 as a target for antitumor therapies, no agents targeting HER3 have been approved for cancer treatment. Most of the agents evaluated in preclinical and clinical trials have been specific monoclonal antibodies (MAbs), with few examples of active immunotherapy directed against this receptor. However, some cancer vaccine formats may generate polyclonal antibodies (PAbs) that replicate the diverse effector mechanisms of MAbs, including ligand neutralization and receptor degradation.
View Article and Find Full Text PDFInt J Biol Macromol
November 2024
Center for Protein Studies/Department of Biochemistry, Faculty of Biology, University of Havana, Havana 10400, Cuba; NanoCancer, Center of Molecular Immunology (CIM), Havana 11600, Cuba. Electronic address:
Sticholysin II (StII), a pore-forming toxin from the marine anemone Stichodactyla helianthus, enhances an antigen-specific cytotoxic T lymphocyte (CTL) response when co-encapsulated in liposomes with a model antigen. This capacity does not depend exclusively on its pore-forming activity and is partially supported by its ability to activate Toll-like receptor 4 (TLR4) in dendritic cells, presumably by interacting with this receptor or by triggering signaling cascades upon binding to lipid membrane. In order to investigate whether the lipid binding capacity of StII is required for immunomodulation, we designed a mutant in which the aromatic amino acids from the interfacial binding site Trp110, Tyr111 and Trp114 were substituted by Ala.
View Article and Find Full Text PDFNat Cardiovasc Res
June 2024
Center of Molecular Immunology, Havana, Cuba.
Heart failure is a progressive syndrome with high morbidity and mortality rates. Here, we suggest that chronic exposure of the heart to risk factors for heart failure damages heart mitochondria, thereby impairing energy production to levels that can suppress the heart's ability to pump blood and repair mitochondria (both energy-consuming processes). As damaged mitochondria accumulate, the heart becomes deprived of energy in a 'self-reinforcing cycle', which can persist after the heart is no longer chronically exposed to (or after antagonism of) the risk factors that initiated the cycle.
View Article and Find Full Text PDFSTAR Protoc
September 2024
Division of Gastroenterology and Hepatology, Enteric Neuroscience Program, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:
Understanding the diversity of gastrointestinal (GI) immune cells, especially in the muscularis propria, is crucial for understanding their role in the maintenance of enteric neurons and smooth muscle and their contribution to GI motility. Here, we present a detailed protocol for isolating single immune cells from the human gastric muscularis propria. We describe steps for tissue preservation, dissection, and dissociation of the muscularis propria.
View Article and Find Full Text PDFJ Biotechnol
September 2024
Immune-regulation Department, Immunology and Immunotherapy Direction. Center of Molecular Immunology, PO Box 16040, Havana, Cuba. Electronic address:
Biol Res
June 2024
Bioprocess R&D Department, Center of Molecular Immunology, 216 Street and 15 Avenue, Atabey, Playa, P.O. Box 16040, 11600, Havana, Cuba.
Heliyon
May 2024
Anses, INRAE, Ecole Nationale Vétérinaire d'Alfort, UMR BIPAR, Laboratoire de Santé Animale, Maisons-Alfort, F-94700, France.
Breast cancer, a global health concern affecting women, has been linked to alterations in the gut microbiota, impacting various aspects of human health. This study investigates the interplay between breast cancer and the gut microbiome, particularly focusing on colonization resistance-an essential feature of the microbiota's ability to prevent pathogenic overgrowth. Using a mouse model of breast cancer, we employ diversity analysis, co-occurrence network analysis, and robustness tests to elucidate the impact of breast cancer on microbiome dynamics.
View Article and Find Full Text PDFFront Med (Lausanne)
May 2024
Institute of General Practice and Interprofessional Care, University Hospital and Faculty of Medicine, Tübingen, Germany.
Introduction: The use of Complementary and Integrative Medicine (CIM) is very popular among the general population in Germany. However, international studies show that nurses, physicians, and other health care professionals (HCPs) at hospitals often do not feel sufficiently informed about different CIM approaches. Moreover, they do not feel trained enough to counsel their patients appropriately.
View Article and Find Full Text PDFNature
March 2024
Genentech Inc., South San Francisco, CA, USA.
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone. However, there remains little consensus on the mechanism(s) of response with this combination.
View Article and Find Full Text PDFSci Rep
January 2024
Center of Molecular Immunology, Calle 216 esq 15, apartado 16040, Atabey, Playa, CP 11300, Havana, Cuba.
SARS-CoV-2 receptor binding domain (RBD) mediates viral entry into human cells through its interaction with angiotensin converting enzyme 2 (ACE2). Most neutralizing antibodies elicited by infection or vaccination target this domain. Such a functional relevance, together with large RBD sequence variability arising during viral spreading, point to the need of exploring the complex landscape of interactions between RBD-derived variants, ACE2 and antibodies.
View Article and Find Full Text PDFToxicon
February 2024
Center for Protein Studies, Faculty of Biology, University of Havana (UH), 25th Street, Corner to J Street, Square of Revolution, Havana, 10400, Cuba; NanoCancer, Molecular Immunology Center (CIM), 216 Street, Corner to 15 Street, Playa, Havana, 11600, Cuba. Electronic address:
Non-viral gene delivery systems offer significant potential for gene therapy due to their versatility, safety, and cost advantages over viral vectors. However, their effectiveness can be hindered by the challenge of efficiently releasing the genetic cargo from endosomes to prevent degradation in lysosomes. To overcome this obstacle, functional components can be incorporated into these systems.
View Article and Find Full Text PDFAlzheimers Res Ther
December 2023
Center of Molecular Immunology (CIM), Calle 216 esquina 15, Siboney, Playa , Havana, CP 11 600, Cuba.
Background: NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, apoptosis and cognitive deficit in an Alzheimer's disease (AD) models. The aim of this study was to assess efficacy and safety of neuroEPO plus.
View Article and Find Full Text PDFJ Interferon Cytokine Res
December 2023
Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
The convergence of life sciences with neurosciences, nanotechnology, data management, and engineering has caused a technological diversification of the biotechnology, pharmaceutical, and medical technology industries, including the phenomenon of digital transformation, which has given rise to the so-called Fourth Industrial Revolution (Industry 4.0). Confronting the COVID-19 pandemic revealed the outstanding response capacity of the scientific community and the biopharmaceutical industry, based on a multidisciplinary and interinstitutional approach that has achieved an unprecedented integration in the history of biomedical science.
View Article and Find Full Text PDFAging Clin Exp Res
November 2023
Clinical Research Direction, Center of Molecular Immunology, Havana, Cuba.
Centenarians are the best example of successful aging in humans. This work aimed to understand if immune status is associated with survival in Cuban centenarians. In a previous study, our group enrolled 43 centenarians and evaluated their immune status and functional capacity.
View Article and Find Full Text PDFNat Cancer
November 2023
Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Methods Mol Biol
September 2023
Center of Molecular Immunology, La Habana, Cuba.
The current chapter focuses on the use of filamentous phages to display and modify biologically active cytokines, with special emphasis on directed evolution of novel variants showing improved receptor binding. Cytokines are essential protein mediators involved in cell-to-cell communication. Their functional importance and the complexity of their interactions with multichain receptors make cytokine engineering a promising tool for the discovery and optimization of therapeutic molecules.
View Article and Find Full Text PDFCommun Biol
August 2023
Center of Molecular Immunology, calle 216 esq 15, apartado 16040, Atabey, Playa, CP 11300, La Habana, Cuba.
Interleukin-2 (IL-2) engineered versions, with biased immunological functions, have emerged from yeast display and rational design. Here we reshaped the human IL-2 interface with the IL-2 receptor beta chain through the screening of phage-displayed libraries. Multiple beta super-binders were obtained, having increased receptor binding ability and improved developability profiles.
View Article and Find Full Text PDFN Engl J Med
August 2023
From St. Anna Children's Cancer Research Institute (CCRI) (J.B., C.R., I.C., S.Z., R.C.A., R.J.H., S.K.B., B.R., E.S., M.D., L.K., K.B.), the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (J.B., C.R., I.C., S.Z., R.C.A., R.J.H., S.K.B., L.P., B.R., A.-K.M., C.D.C., E.S., C.B., L.D., K.B.), CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (J.B., C.R., S.Z., R.C.A., R.J.H., S.K.B., B.R., A.T., M.C., M.S., C.D.C., E.S., J.M., C.B., J.T.H., K.B.), and the Departments of Pediatrics and Adolescent Medicine (C.R., R.J.H., E.S., L.K., K.B.) and Dermatology (A.-K.M., L.D.), the Institute for Hygiene and Applied Immunology (R.P., J.B.H.) and the Institute of Immunology (W.F.P.), Center for Pathophysiology, Infectiology, and Immunology, and the Institute of Artificial Intelligence, Center for Medical Data Science (C.B.), Medical University of Vienna, the St. Anna Children's Hospital (E.S., L.K., K.B.), the Department of Structural and Computational Biology, Max Perutz Labs, and the Faculty of Mathematics, University of Vienna (J.M.), Vienna, and the Karl Landsteiner University of Health Sciences, Krems (W.F.P.) - all in Austria; Hématopoïèse et Immunologie (HEMATIM) Unité de Recherche 4666, Université de Picardie Jules Verne (J.P., T.B., L.D.C.), and Service d'Hématologie Biologique (Hematology Diagnostic Lab), Centre Hospitalier Universitaire d'Amiens (T.B.), Amiens, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM and Paul Sabatier University (Unité Mixte de Recherche 1291), and Centre National de la Recherche Scientifique (Unité Mixte de Recherche 5051) (B.C., L.P., L.D.), and the Institute of Cardiovascular and Metabolic Diseases (I2MC), INSERM and Paul Sabatier University (Unité Mixte de Recherche 1297) (J.V.), Toulouse, and Service d'Hématologie Biologique (Hematology Diagnostic Lab), Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, the University of Paris, and the Laboratory of Excellence for Red Cells, Laboratory of Excellence GR-Ex, Paris (L.D.C.) - all in France; the Biosafety Division, Research Institute, National Center for Geriatrics and Gerontology, Obu, Japan (M.F., R.K., A.N.); the National Institute of Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, and the Computational Modeling Group, Oswaldo Cruz Foundation (Fiocruz), Eusébio - both in Brazil (B.C.); the Molecular Cell Biology Lab, Department of Molecular Hematology, Sanquin Research, the Vascular Cell Biology Lab, Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, and the Leeuwenhoek Center for Advanced Microscopy, Section of Molecular Cytology, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam (R.S., J.D.B.), the Department of Human Genetics (C.I.M., H.G.B., A.H.) and the Radboud University Medical Center for Infectious Diseases, Department of Internal Medicine, Radboud University Medical Center, Nijmegen (C.I.M., A.H.), the Department of Clinical Genetics, Maastricht University Medical Center, and GROW School for Oncology and Reproduction, Maastricht University, Maastricht (H.G.B.), and the Department of Pediatrics, Slingeland Hospital, Doetinchem (J.E.N.-F.) - all in the Netherlands; the Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg (F.L.H., K.K.), University Children's Hospital Oldenburg, Department of Neuropediatrics, Oldenburg (T.L., S.I.), and the Center for Pediatrics and Adolescent Medicine, Department of Pediatric Kidney, Liver, and Metabolic Diseases and Neuropediatrics, Hannover Medical School, Hannover (S.I.) - all in Germany; the Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health (S.A.), and the Allergy and Clinical Immunology Department, Mofid Children's Hospital (Z.C.), Shahid Beheshti University of Medical Sciences, Tehran, Iran; the Clinical Immunology and Primary Immunodeficiencies Unit, Allergy and Clinical Immunology Department (L.A., A.D.-M.), and the Pediatric Rheumatology Department (E.I., J.A., J.C.-H.), Hospital Sant Joan de Déu, the Study Group for Immune Dysfunction Diseases in Children, Institut de Recerca Sant Joan de Déu (L.A., E.I., A.D.-M., J.A., J.C.-H.), and the Department of Surgery and Surgical Specializations, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (L.A., J.A.), Barcelona, and the Pediatric Infectious Diseases, Rheumatology, and Immunology Unit (P.S.M., M.C.-L., O.N.) and the Department of Pathology (R.Á.P., R.C.-P.), Hospital Universitario Virgen del Rocío, Institute of Biomedicine of Seville, Seville - all in Spain; the Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh (J.A.Y.); the Department of Cellular and Molecular Medicine and the Section of Cell and Developmental Biology, University of California, San Diego, La Jolla (D.T.); and the Primary Immunodeficiency Group, Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom (K.R.E., S.H.).
Background: Increasing evidence links genetic defects affecting actin-regulatory proteins to diseases with severe autoimmunity and autoinflammation, yet the underlying molecular mechanisms are poorly understood. Dedicator of cytokinesis 11 (DOCK11) activates the small Rho guanosine triphosphatase (GTPase) cell division cycle 42 (CDC42), a central regulator of actin cytoskeleton dynamics. The role of DOCK11 in human immune-cell function and disease remains unknown.
View Article and Find Full Text PDFImmun Ageing
June 2023
Department of Clinical Immunology, Center of Molecular Immunology, 216 St, Corner 15, PO Box 16040, Atabey, Havana, Cuba.
Aging is a gradual, continuous series of natural changes in biological, physiological, immunological, environmental, psychological, behavioral, and social processes. Aging entails changes in the immune system characterized by a decrease in thymic output of naïve lymphocytes, an accumulated chronic antigenic stress notably caused by chronic infections such as cytomegalovirus (CMV), and immune cell senescence with acquisition of an inflammatory senescence-associated secretory phenotype (SASP). For this reason, and due to the SASP originating from other tissues, aging is commonly accompanied by low-grade chronic inflammation, termed "inflammaging".
View Article and Find Full Text PDFClin Microbiol Infect
September 2023
Institute for Medical Microbiology and Infection Control, Hospital of Johann Wolfgang Goethe University, Frankfurt, Germany.
Objectives: To analyse carbapenemases in Proteus mirabilis and assess the performance of carbapenemase detection assays.
Methods: Eighty-one clinical P. mirabilis isolates with high-level resistance at least to ampicillin (>32 mg/L) or previous detection of carbapenemases were selected and investigated by three susceptibility testing methods (microdilution, automated susceptibility testing, and disk diffusion), six phenotypic carbapenemase assays (CARBA NP, modified carbapenemase inactivation method [CIM], modified zinc-supplemented CIM, simplified CIM, faropenem, and carbapenem-containing agar), two immunochromatographic assays, and whole-genome sequencing.
Microbiol Spectr
June 2023
Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
An isolate of Morganella morganii (MMOR1) that tested susceptible to 3/4-generation cephalosporins and intermediate to meropenem was characterized as positive for NDM and IMP carbapenemases by NG-Test CARBA 5. Our objective was to further investigate this result, given the inconsistent susceptibility profile and unusual epidemiological profile for our region. The MMOR1 isolate was retested for antimicrobial susceptibilities and characterized for carbapenemase production.
View Article and Find Full Text PDFBiol Res
May 2023
Bioprocess R&D Department, Center of Molecular Immunology, 216 Street and 15 Avenue, Atabey, Playa, P.O. Box 16040, 11600, Havana, Cuba.
The COVID-19 pandemic has caused a large number of diseases worldwide. There are few vaccines to constrain this disease and the value of them is high. In this sense, the antigens of the vaccine platform Soberana, the receptor binding domain from SARS-CoV-2 Spike protein, both the monomeric (mRBD) and dimeric (dRBD) forms, have been developed.
View Article and Find Full Text PDFCell Commun Signal
April 2023
Innovative Immunotherapy Alliance S.A., Mariel, Artemisa, Cuba.
Androgen deprivation therapy (ADT) is a standard therapy for prostate cancer (PCa). Though disseminated disease is initially sensitive to ADT, an important fraction of the patients progresses to castration-resistant prostate cancer (CRPC). For this reason, the identification of novel effective therapies for treating CRPC is needed.
View Article and Find Full Text PDF